tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Kevin Kedra, 8 are a BUY (44.44%), 8 are a HOLD (44.44%), 2 are a SELL (11.11%).
Analyst Kevin Kedra, currently employed carries an average stock price target met ratio of 75% that have a potential upside of 66.24% achieved within 484 days.
Kevin Kedra’s has documented 31 price targets and ratings displayed on 4 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on ELAN, Elanco Animal Health at 17-Jun-2021.
Analyst best performing recommendations are on LXRX (LEXICON PHARMACEUTICALS).
The best stock recommendation documented was for LXRX (LEXICON PHARMACEUTICALS) at 9/11/2019. The price target of $3 was fulfilled within 7 days with a profit of $0.8 (36.36%) receiving and performance score of 51.95.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$4
$2.73 (214.96%)
$8
11 months 12 days ago
(12-Dec-2023)
4/15 (26.67%)
$2.82 (238.98%)
47
Buy
$10
$8.73 (687.40%)
$10
2 years 1 months 21 days ago
(03-Oct-2022)
0/2 (0%)
$7.55 (308.16%)
Hold
$7
$5.91 (542.20%)
3 years 9 months 26 days ago
(29-Jan-2021)
3/3 (100%)
$1.33 (13.05%)
55
Buy
$2
$0.73 (57.48%)
3 years 9 months 26 days ago
(29-Jan-2021)
2/6 (33.33%)
$-5.91 (-74.72%)
409
Hold
3 years 10 months 9 days ago
(15-Jan-2021)
1/1 (100%)
$0.8 (36.36%)
7
What Year was the first public recommendation made by Kevin Kedra?
